34 related articles for article (PubMed ID: 10481939)
1. Influence of physiologic hormonal modification and of hormonal treatment in a patient with a history of migraine with aura.
Maggioni F; Palmieri A; Tropea M; Zanchin G
J Headache Pain; 2008 Apr; 9(2):129-31. PubMed ID: 18265933
[TBL] [Abstract][Full Text] [Related]
2. Change in Estradiol Levels among Premenopausal Patients with Breast Cancer Treated Using Leuprolide Acetate 11.25 Milligrams 3-Month Depot and Tamoxifen.
Lee YJ; Wu ZY; Kim HJ; Lee JW; Chung IY; Kim J; Lee SB; Son BH; Kim SB; Jung JH; Gong G; Ahn SH; Ko B
J Breast Cancer; 2020 Oct; 23(5):553-559. PubMed ID: 33154830
[TBL] [Abstract][Full Text] [Related]
3. Long-Acting Luteinizing Hormone-Releasing Hormone Agonist for Ovarian Hyperstimulation Induced by Tamoxifen for Breast Cancer.
Kojima N; Yamasaki Y; Koh H; Miyashita M; Morita H
Case Rep Obstet Gynecol; 2018; 2018():4931852. PubMed ID: 29607235
[TBL] [Abstract][Full Text] [Related]
4. Spotlight on triptorelin in the treatment of premenopausal women with early-stage breast cancer.
Venturelli M; Guaitoli G; Omarini C; Moscetti L
Breast Cancer (Dove Med Press); 2018; 10():39-49. PubMed ID: 29551913
[TBL] [Abstract][Full Text] [Related]
5. Ovarian hyperstimulation in premenopausal women during adjuvant tamoxifen treatment for endocrine-dependent breast cancer: A report of two cases.
Madeddu C; Gramignano G; Kotsonis P; Paribello F; Macciò A
Oncol Lett; 2014 Sep; 8(3):1279-1282. PubMed ID: 25120706
[TBL] [Abstract][Full Text] [Related]
6. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
Sharma R; Hamilton A; Beith J
Cochrane Database Syst Rev; 2008 Oct; (4):CD004562. PubMed ID: 18843661
[TBL] [Abstract][Full Text] [Related]
7. Ovarian hyperstimulation without elevated serum estradiol associated with pure follicle-stimulating hormone-secreting pituitary adenoma.
Shimon I; Rubinek T; Bar-Hava I; Nass D; Hadani M; Amsterdam A; Harel G
J Clin Endocrinol Metab; 2001 Aug; 86(8):3635-40. PubMed ID: 11502789
[TBL] [Abstract][Full Text] [Related]
8. Successful co-treatment with LHRH-agonist for ovarian over-stimulation and cystic formation in premenopausal tamoxifen exposure.
Cohen I; Tepper R; Figer A; Flex D; Shapira J; Beyth Y
Breast Cancer Res Treat; 1999 May; 55(2):119-25. PubMed ID: 10481939
[TBL] [Abstract][Full Text] [Related]
9. Ovarian overstimulation and cystic formation in premenopausal tamoxifen exposure: comparison between tamoxifen-treated and nontreated breast cancer patients.
Cohen I; Figer A; Tepper R; Shapira J; Altaras MM; Yigael D; Beyth Y
Gynecol Oncol; 1999 Feb; 72(2):202-7. PubMed ID: 10021302
[TBL] [Abstract][Full Text] [Related]
10. Ovarian cyst formation in two pre-menopausal patients treated with tamoxifen for breast cancer.
Shulman A; Cohen I; Altaras MM; Maymon R; Ben-Nun I; Tepper R; Beyth Y
Hum Reprod; 1994 Aug; 9(8):1427-9. PubMed ID: 7989499
[TBL] [Abstract][Full Text] [Related]
11. Successful management of an ovarian enlargement resembling ovarian hyperstimulation in a premenopausal breast cancer patient receiving tamoxifen with cotreatment of GnRH-agonist.
Turan C; Unal O; Dansuk R; Guzelmeric K; Cengizoglu B; Esim E
Eur J Obstet Gynecol Reprod Biol; 2001 Jul; 97(1):105-7. PubMed ID: 11435021
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic approach to ovarian cysts in tamoxifen-treated women with breast cancer.
Shushan A; Peretz T; Mor-Yosef S
Int J Gynaecol Obstet; 1996 Mar; 52(3):249-53. PubMed ID: 8775677
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
